A17.1 Meningeal tuberculoma

Name of the Condition

• Meningeal tuberculoma

Summary

Meningeal tuberculoma is a localized, chronic inflammatory lesion caused by Mycobacterium tuberculosis infection within the meninges, the protective membranes surrounding the brain and spinal cord. It represents a form of extrapulmonary tuberculosis (TB) and may develop as a complication of tuberculous meningitis or from hematogenous spread of TB bacteria. The condition typically presents as a mass-like lesion and can lead to neurological symptoms depending on its size and location.

Causes

Meningeal tuberculoma is caused by the presence of Mycobacterium tuberculosis in the meninges, often resulting from the spread of TB bacteria from a primary infection site, such as the lungs, to the central nervous system. The bacteria may reach the meninges through the bloodstream or by direct extension from adjacent infected tissues. The lesion forms as a granulomatous reaction to the bacterial infection, characterized by caseous necrosis and fibrous encapsulation.

Risk Factors

• Active or latent tuberculosis infection
• Weakened immune system (e.g., HIV/AIDS, immunosuppressive therapy)
• Malnutrition or chronic illness
• Prior history of tuberculous meningitis
• Lack of adequate TB treatment or preventive care

Symptoms

• Persistent headache
• Focal neurological deficits (e.g., weakness, numbness, vision changes)
• Seizures
• Cognitive or behavioral changes
• Nausea or vomiting
• Fever (less common than in acute meningitis)

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging, and laboratory testing. Magnetic resonance imaging (MRI) or computed tomography (CT) scans may reveal characteristic lesions. Cerebrospinal fluid (CSF) analysis may show elevated protein, lymphocytic pleocytosis, or positive TB-specific tests (e.g., PCR, culture). Biopsy of the lesion may be performed to confirm the diagnosis when imaging or CSF results are inconclusive.

Treatment Options

• Antitubercular therapy: Standard multi-drug regimens (e.g., isoniazid, rifampin, pyrazinamide, ethambutol) are the mainstay of treatment, typically administered for 6–12 months.
• Corticosteroids: May be used to reduce inflammation and prevent complications, especially if associated with tuberculous meningitis.
• Surgical intervention: Considered for lesions causing mass effect, hydrocephalus, or when diagnosis is uncertain.

Prognosis and Follow-Up

Prognosis depends on the size and location of the lesion, timeliness of treatment, and overall health status. Early diagnosis and adherence to antitubercular therapy improve outcomes. Follow-up includes monitoring for treatment response, resolution of symptoms, and potential recurrence. Long-term neurological sequelae may occur in some cases.

Complications

• Hydrocephalus (due to obstruction of CSF flow)
• Seizure disorders
• Permanent neurological deficits (e.g., motor or cognitive impairment)
• Recurrence of tuberculoma if treatment is incomplete

Lifestyle & Prevention

• Complete the full course of prescribed antitubercular therapy to prevent relapse.
• Maintain good nutrition and overall health to support immune function.
• Avoid exposure to individuals with active TB, especially in high-risk settings.
• Follow public health guidelines for TB prevention, including screening and treatment of latent infection.

When to Seek Professional Help

Seek immediate medical attention if experiencing:

• Sudden severe headache
• New or worsening neurological symptoms (e.g., weakness, confusion, vision changes)
• Seizures
• Persistent fever or worsening symptoms during TB treatment

Tips for Medical Coders

Code A17.1 is assigned for meningeal tuberculoma. Documentation should specify the anatomical location (e.g., cerebral, spinal) and confirm the tuberculous etiology. Differentiate from other granulomatous lesions or masses by noting TB-specific findings (e.g., CSF analysis, imaging, biopsy). Ensure the diagnosis aligns with clinical criteria and exclude overlapping conditions (e.g., tuberculous meningitis) when applicable.